1、 LIM S K, LEE S A, KIM C-W,et al.High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration[J].Hemodial Int,2019,23(1): 69-76. LIM S K, LEE S A, KIM C-W,et al.High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration[J].Hemodial Int,2019,23(1): 69-76.
2、 YOSHIDA T, YOSHIDA S, OKADA H,et al.Risk factors for decreased teicoplanin trough concentrations during initial dosing in critically ill patients[J].Pharmazie,2019,74(2): 120-124. YOSHIDA T, YOSHIDA S, OKADA H,et al.Risk factors for decreased teicoplanin trough concentrations during initial dosing in critically ill patients[J].Pharmazie,2019,74(2): 120-124.
3、 BYRNE C J, ROBERTS J A, MCWHINNEY B,et al.Variability in trough totaland unbound teicoplanin concentrations and achievement oftherapeutic drug monitoring targets in adult patients with hematological malignancy[J].Antimicrob Agents Chemother,2017,61(6): e02466-16. BYRNE C J, ROBERTS J A, MCWHINNEY B,et al.Variability in trough totaland unbound teicoplanin concentrations and achievement oftherapeutic drug monitoring targets in adult patients with hematological malignancy[J].Antimicrob Agents Chemother,2017,61(6): e02466-16.
4、 KIM S-H, KANG C-I, HUH K,et al.Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy[J].Eur J Clin Microbiol Infect Dis,2019,38(11): 2113-2120. KIM S-H, KANG C-I, HUH K,et al.Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy[J].Eur J Clin Microbiol Infect Dis,2019,38(11): 2113-2120.
5、 LI H, GAO L, ZHOU L,et al.Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients[J].Basic Clin Pharmacol Toxicol,2020,126(3): 277-288. LI H, GAO L, ZHOU L,et al.Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients[J].Basic Clin Pharmacol Toxicol,2020,126(3): 277-288.
6、 KONTOU A, SARAFIDIS K, BEGOU O,et al.Population pharmacokinetics of teicoplanin in preterm and term neonates: is it time for a new dosing regimen?[J].Antimicrob Agents Chemother,2020, 64(4): e01971-19. KONTOU A, SARAFIDIS K, BEGOU O,et al.Population pharmacokinetics of teicoplanin in preterm and term neonates: is it time for a new dosing regimen?[J].Antimicrob Agents Chemother,2020, 64(4): e01971-19.
7、 TSUTSUURA M, MORIYAMA H, KOJIMA N,et al.The monitoring of vancomycin: a systematic review and meta-analyses of area under theconcentration-time curve-guided dosing and trough-guided dosing[J].BMC Infect Dis,2021, 21(1):153. TSUTSUURA M, MORIYAMA H, KOJIMA N,et al.The monitoring of vancomycin: a systematic review and meta-analyses of area under theconcentration-time curve-guided dosing and trough-guided dosing[J].BMC Infect Dis,2021, 21(1):153.
8、 ODA K, HASHIGUCHI Y, KIMURA T,et al.Performance of area under theconcentration-time curve estimations of vancomycin with limited sampling by a newly developed web application[J].Pharm Res,2021, 38(4):637-646. ODA K, HASHIGUCHI Y, KIMURA T,et al.Performance of area under theconcentration-time curve estimations of vancomycin with limited sampling by a newly developed web application[J].Pharm Res,2021, 38(4):637-646.
9、 HEINE R T, KEIZER R J, van STEEG K,et al.Prospective validation of amodel-informed precision dosing tool for vancomycin in intensive carepatients[J].Br J Clin Pharmacol,2020,86(12): 2497-2506. HEINE R T, KEIZER R J, van STEEG K,et al.Prospective validation of amodel-informed precision dosing tool for vancomycin in intensive carepatients[J].Br J Clin Pharmacol,2020,86(12): 2497-2506.
10、 WICHA S G, M?RTSON A-G, NIELSEN E I,et al.From therapeutic drug monitoring to model-informed precision dosing for antibiotics[J].Clin Pharmacol Ther,2021,109(4): 928-941. WICHA S G, M?RTSON A-G, NIELSEN E I,et al.From therapeutic drug monitoring to model-informed precision dosing for antibiotics[J].Clin Pharmacol Ther,2021,109(4): 928-941.
11、 RAMOS-MARTíN V, JOHNSON A, MCENTEE L,et al.Pharmacodynamics of teicoplanin against MRSA[J].J Antimicrob Chemother,2017, 72(12): 3382-3389. RAMOS-MARTíN V, JOHNSON A, MCENTEE L,et al.Pharmacodynamics of teicoplanin against MRSA[J].J Antimicrob Chemother,2017, 72(12): 3382-3389.
12、 MATSUMOTO K, WATANABE E, KANAZAWA N, et al.Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections[J].Clin Pharmacol,2016(8): 15-18. MATSUMOTO K, WATANABE E, KANAZAWA N, et al.Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections[J].Clin Pharmacol,2016(8): 15-18.
13、 WATANABE E, MATSUMOTO K, IKAWA K,et al.Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in amurine thigh infection model[J].J Glob Antimicrob Resist,2021(24): 83-87. WATANABE E, MATSUMOTO K, IKAWA K,et al.Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in amurine thigh infection model[J].J Glob Antimicrob Resist,2021(24): 83-87.
14、 HANAI Y, TAKAHASHI Y, NIWA T,et al.Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: a systematic review and meta-analysis[J].J Clin Pharm Ther,2021,46(3): 622-632. HANAI Y, TAKAHASHI Y, NIWA T,et al.Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: a systematic review and meta-analysis[J].J Clin Pharm Ther,2021,46(3): 622-632.
15、 UEDA T, TAKESUE Y, NAKAJIMA K, et al.Clinical efficacy and safety inpatients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days[J].BMC Pharmacol Toxicol,2020, 21(1): 50. UEDA T, TAKESUE Y, NAKAJIMA K, et al.Clinical efficacy and safety inpatients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days[J].BMC Pharmacol Toxicol,2020, 21(1): 50.
